The influence of statin therapy on DDAVP response in patients with Type 1 von Willebrand disease or mild Hemophilia A.
- Conditions
- Von Willebrand diseaseZiekte van Von WillebrandHemophilia AHemofilie ABloederziekte
- Registration Number
- NL-OMON26976
- Lead Sponsor
- Academic Medical Center, Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Mild hemophilia A, or;
2. Type 1 von Willebrand disease;
Exclusion Criteria
1. Moderate/Severe hemophilia A;
2. Type 2 or 3 von Willebrand diseas;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Von Willebrand factor antigen, von Willebrand factor activity and von Willebrand Factor propeptide plasma levels after DDAVP stimulation, during statin therapy;<br /><br>2. Factor VIII activity and factor VIII antigen plasma levels after DDAVP stimulation, during statin therapy. <br>
- Secondary Outcome Measures
Name Time Method Von Willebrand factor multimers, ADAMTS13 and tPA plasmalevels after DDAVP stimulation during statin therapy.